Neurocrine Biosciences
NBIX
$138.48
Share price
1.71%
Change (1 day)
41.09%
Change (1 year)
Categories
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.
Neurocrine Biosciences (NBIX) - Net assets
Net assets on the balance sheet as of March 2024 : $2.38 B
According to Neurocrine Biosciences
's latest financial reports the company has $2.38 B in net assets.
A company’s net assets is the sum of its assets minus the sum of its liabilities.
Neurocrine Biosciences - Net assets on balance sheet (from 2001 to 2024)
Net assets by year
| Year | Net assets | Change |
|---|---|---|
| 2023-12-31 | $2.23 B | 30.69% |
| 2022-12-31 | $1.70 B | 24.29% |
| 2021-12-31 | $1.37 B | 22% |
| 2020-12-31 | $1.12 B | 76.83% |
| 2019-12-31 | $0.63 B | 32.48% |
| 2018-12-31 | $0.48 B | 29.19% |
| 2017-12-31 | $0.37 B | 18.19% |
| 2016-12-31 | $0.31 B | -25.82% |
| 2015-12-31 | $0.42 B | 103.38% |
| 2014-12-31 | $0.20 B | 73.32% |
| 2013-12-31 | $0.12 B | -22% |
| 2012-12-31 | $0.15 B | 156.94% |
| 2011-12-31 | $60.08 M | 210.58% |
| 2010-12-31 | $19.34 M | 389.25% |
| 2009-12-31 | $3.95 M | -89.25% |
| 2008-12-31 | $36.77 M | -69.02% |
| 2007-12-31 | $0.11 B | -62.28% |
| 2006-12-31 | $0.31 B | -19.33% |
| 2005-12-31 | $0.39 B | -0.95% |
| 2004-12-31 | $0.39 B | 0.69% |
| 2003-12-31 | $0.39 B | 74.41% |
| 2002-12-31 | $0.22 B | -27.75% |
| 2001-12-31 | $0.31 B |
Net assets for similar companies or competitors
| Company | Net assets | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $89.28 B | 3,642.01% | 🇺🇸 USA |
 AbbVie ABBV | $10.39 B | 335.73% | 🇺🇸 USA |
 Eli Lilly LLY | $12.89 B | 440.52% | 🇺🇸 USA |
 Repligen
RGEN | $1.97 B | -17.41% | 🇺🇸 USA |
 Athersys ATHX | -$36.4 M | -101.53% | 🇺🇸 USA |
 ANI Pharmaceuticals ANIP | $0.45 B | -80.82% | 🇺🇸 USA |
 Palatin Technologies PTN | -$11.39 M | -100.48% | 🇺🇸 USA |
 Royalty Pharma RPRX | $10.08 B | 322.63% | 🇬🇧 UK |